Cipla shares rally 8% to hit 52-week high on strong Q3 earnings

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Shares of Cipla rallied as much as 8 percent to hit a 52-week high of Rs 1,425 in trade on January 23, a day after the company reported a strong performance in Q3 on all key parameters of profit, revenue and profitability.

The company's net profit for the quarter grew 32.7 percent on-year to Rs 1,049 crore despite an exceptional loss of Rs 194.8 crore. The bottomline growth was also aided by a 14.2 percent on-year increase in revenue to Rs 6,544 crore in the October-December period.

Growth was largely broad-based across markets as the company clocked in its highest ever North American sales at  $230 million, up 18 percent on year. The India business grew nearly 12 percent to Rs 2,859  crore, whereas sales from the South Africa recorded a near 10 percent rise to Rs 603 crore.

Growth in the India business was driven by a strong performance across branded prescription, trade generics and consumer health, while that in North America was supported by continuing momentum in key assets and robust demand in base business along with some year-end buying.

The South Africa business also benefitted from the increase in revenue in local currency terms. This performance was supported by positive traction in prescription, OTC (over-the-counter) and tender.

At close, shares of Cipla were  7 percent higher at Rs 1,409 on the NSE. The strong quarterly performance also aided the company's operating margins as it expanded to 26.5 percent in Q3 as against 24.2 percent a year ago.

The drugmaker has also filed the generic of asthama drug Symbicort and one other inhalation asset in Q3. It also plans to launch four peptides in FY25.

Meanwhile, the company also incorporated its arm to sell, distribute pharma drugs in Mexico.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.